JP2024529070A5 - - Google Patents
Info
- Publication number
- JP2024529070A5 JP2024529070A5 JP2024507174A JP2024507174A JP2024529070A5 JP 2024529070 A5 JP2024529070 A5 JP 2024529070A5 JP 2024507174 A JP2024507174 A JP 2024507174A JP 2024507174 A JP2024507174 A JP 2024507174A JP 2024529070 A5 JP2024529070 A5 JP 2024529070A5
- Authority
- JP
- Japan
- Prior art keywords
- heterocycloalkyl
- cycloalkyl
- independently
- pharmaceutically acceptable
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110919812.6 | 2021-08-11 | ||
| CN202110919812 | 2021-08-11 | ||
| CN202111188963.5 | 2021-10-12 | ||
| CN202111188963 | 2021-10-12 | ||
| CN202210918443.3 | 2022-08-01 | ||
| CN202210918443 | 2022-08-01 | ||
| PCT/CN2022/111893 WO2023016529A1 (zh) | 2021-08-11 | 2022-08-11 | 作为atr抑制剂的萘啶衍生物及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024529070A JP2024529070A (ja) | 2024-08-01 |
| JP2024529070A5 true JP2024529070A5 (https=) | 2025-08-19 |
Family
ID=85199870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024507174A Pending JP2024529070A (ja) | 2021-08-11 | 2022-08-11 | Ａｔｒ阻害剤としてのナフチリジン誘導体およびその調製方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240317741A1 (https=) |
| EP (1) | EP4385992A4 (https=) |
| JP (1) | JP2024529070A (https=) |
| CN (1) | CN117642401A (https=) |
| AU (1) | AU2022325376A1 (https=) |
| CA (1) | CA3227336A1 (https=) |
| TW (1) | TWI831325B (https=) |
| WO (1) | WO2023016529A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI656121B (zh) * | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | ２－（嗎啉－４－基）－１，７－萘啶 |
| CA3011189C (en) * | 2016-01-14 | 2024-02-20 | Bayer Pharma Aktiengesellschaft | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines |
| WO2018153970A1 (en) * | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Solid forms of 2-[(3r)-3-methylmorpholin-4-yl]-4-(1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine |
| AU2019373416A1 (en) * | 2018-10-30 | 2021-06-10 | Repare Therapeutics Inc. | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors |
| US20240043419A1 (en) * | 2020-09-27 | 2024-02-08 | Medshine Discovery Inc. | Class of 1,7-naphthyridine compounds and application thereof |
-
2022
- 2022-08-11 WO PCT/CN2022/111893 patent/WO2023016529A1/zh not_active Ceased
- 2022-08-11 AU AU2022325376A patent/AU2022325376A1/en active Pending
- 2022-08-11 TW TW111130300A patent/TWI831325B/zh active
- 2022-08-11 EP EP22855509.0A patent/EP4385992A4/en active Pending
- 2022-08-11 US US18/578,384 patent/US20240317741A1/en active Pending
- 2022-08-11 JP JP2024507174A patent/JP2024529070A/ja active Pending
- 2022-08-11 CN CN202280050285.2A patent/CN117642401A/zh active Pending
- 2022-08-11 CA CA3227336A patent/CA3227336A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024529070A5 (https=) | ||
| JP2024520481A5 (https=) | ||
| JP2024050527A5 (https=) | ||
| RU2344123C9 (ru) | 3,4-дизамещенные циклобутен-1,2-дионы как лиганды схс-хемокинового рецептора | |
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| JP2011509309A5 (https=) | ||
| RU2350605C2 (ru) | Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ | |
| JP2020007311A5 (https=) | ||
| JP2005504789A5 (https=) | ||
| JP2014503574A5 (https=) | ||
| RU2013156074A (ru) | Диазакарбазолы и способы применения | |
| JP2012512891A5 (https=) | ||
| JP2022511477A5 (https=) | ||
| RU2014141674A (ru) | 3,5-диаминопиразоловые ингибиторы киназы | |
| JP2006507355A5 (https=) | ||
| JP2023531709A5 (https=) | ||
| JP2023552610A5 (https=) | ||
| JP2014520108A5 (https=) | ||
| JP2023543254A5 (https=) | ||
| RU2010113358A (ru) | Гуанидинсодержащие соединения, применимые в качестве антагонистов мускариновых рецепторов | |
| JP2023531495A5 (https=) | ||
| JP2024534420A5 (https=) | ||
| RU2020126188A (ru) | Соединения тетрагидроизохинолина | |
| JP2014521609A5 (https=) | ||
| JP2025508896A5 (https=) |